Occurrence of irAEs after Immune Checkpoint Inhibitor Rechallenge: An Updated Meta-Analysis

Figure 5

(a) Subgroup analyses of the association between ICI rechallenge and high-grade irAE occurrence after ICI rechallenge at different age stratification. CI, confidence interval; ICIs, immune checkpoint inhibitors; irAEs, immune-related adverse events; OR, odds ratio. High-grade was considered grade ≥3. (b) Subgroup analyses of the association between ICI rechallenge and high-grade irAE occurrence after ICI rechallenge at different gender stratification. The male subgroup is defined as males comprising more than 50% of the study population, and the female subgroup is defined as females comprising more than 50% of the study population. CI, confidence interval; ICIs, immune checkpoint inhibitors; irAEs, immune-related adverse events; OR, odds ratio. High-grade was considered grade ≥3.

(a)

(b)